Name and address of Governmental Lender’s counsel.

All Advances shall be disbursed from whichever office or other place [[Organization B:Organization]] may designate from time to time and, together with any and all other Obligations of [[Organization A:Organization]] to [[Organization B:Organization]] or Lenders, shall be charged to [[Organization A:Organization]]' Account on [[Organization B:Organization]]'s books. During the Term, [[Organization A:Organization]]

The agreement of Lenders to make any Advance requested to be made on any date (including the initial Advance), is subject to the satisfaction of the following conditions precedent as of the date such Advance is made:

If Buyer proposes a new blade model, Seller will notify Buyer of any new product specific tools and modifications to the Production Facility and/or the Storage Facility that will be required for the production of the new model. It will be the responsibility of Buyer to provide and deliver such product specific tools to Seller at Buyer’s sole cost. Seller will quote a price for such new blade model and establish an initial Bill of Materials and Baseline Price Schedule for such model. [...​...].

In the event that Buyer proposes a new blade model during the Term, the parties agree to the Minimum Volume Obligation under this Agreement shall remain the same and any remaining Minimum Volume Obligation for a Purchase Time Period shall be applied to the new model provided that no other model is being produced in which case the parties shall agree on the allocation between the models. Seller shall quote a price for such new blade model and establish an initial bill of material, and delivery schedule for such model based on a maximum of […​…] calculated using agreed on […​…]. The price quoted by Seller shall also include […​…] shall be documented in writing by Seller).

Test an additional in vivo model (e.g. ​)

Suspensions of ​ were tolerable, but not pharmacologically active in a rabbit hyperpermeability model.

Suspensions of a ​ were tolerable and pharmacologically active in a pig uveitis model.

IFRS 9 replaces the ‘incurred loss model’ in IAS 39 with an ‘expected credit loss’ model. The measurement uses a dual measurement approach, under which the loss allowance is measured as either 12 month expected credit losses or lifetime expected credit losses. The standard also introduces new presentation and disclosure requirements.

Minimum Amount of Each Revolving Advance. Each Revolving Advance (other than a Revolving Advance of Revolving Loans to repay a Reimbursement Obligation) shall be in a minimum amount of $5,000,000 (or the Equivalent Amount if denominated in an Agreed Currency other than Dollars) and in multiples of $1,000,000 (or the Equivalent Amount if denominated in an Agreed Currency other than Dollars) if in excess thereof; provided, however, that any Floating Rate Advance may be in the Dollar Amount of the unused total Revolving Loan Commitment in respect of the applicable Class.